Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q2 2025 value amounting to $15.0 million.

  • Crinetics Pharmaceuticals' Gains from Investment Securities rose 603.93% to $15.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $85.2 million, marking a year-over-year increase of 51383.46%. This contributed to the annual value of $13.7 million for FY2024, which is 822.55% up from last year.
  • Crinetics Pharmaceuticals' Gains from Investment Securities amounted to $15.0 million in Q2 2025, which was up 603.93% from $15.3 million recorded in Q1 2025.
  • Crinetics Pharmaceuticals' 5-year Gains from Investment Securities high stood at $72.2 million for Q4 2024, and its period low was -$708000.0 during Q4 2023.
  • Its 5-year average for Gains from Investment Securities is $11.4 million, with a median of $10.2 million in 2022.
  • In the last 5 years, Crinetics Pharmaceuticals' Gains from Investment Securities skyrocketed by 13852909.68% in 2022 and then crashed by 33600.0% in 2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $5.1 million in 2021, then crashed by 94.13% to $300000.0 in 2022, then crashed by 336.0% to -$708000.0 in 2023, then skyrocketed by 10290.82% to $72.2 million in 2024, then crashed by 79.22% to $15.0 million in 2025.
  • Its Gains from Investment Securities stands at $15.0 million for Q2 2025, versus $15.3 million for Q1 2025 and $72.2 million for Q4 2024.